# A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients

> **NCT03244085** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** QL-007 tablet

## Key facts

- **NCT ID:** NCT03244085
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-20
- **Primary completion:** 2018-10-30
- **Final completion:** 2018-12-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2018-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03244085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03244085, "A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03244085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*